Raajit K. Rampal, MD, PhD, discusses the MANIFEST-2 trial, a phase 3 study comparing ruxolitinib vs pelabresib and ruxolitinib combined with placebo for the treatment of myelofibrosis.
Raajit K. Rampal, MD, PhD, hematologic oncologist at Memorial Sloan Kettering Cancer Center, discusses the MANIFEST-2 trial, a phase 3 study comparing ruxolitinib (Jakafi) to pelabresib (CPI-0610) and ruxolitinib combined with placebo.
The trial enrolled untreated patients with symptomatic and enlarged spleens due to myelofibrosis.
Transcription:
0:09 | I presented the phase 3 data for the MANIFEST-2 trial, which was a phase 3 trial that was comparing ruxolitinib and pelabresib, which is a BET inhibitor, vs ruxolitinib and placebo. This was a trial of untreated patients with myelofibrosis who had symptoms and an enlarged spleen. It was a double-blind, placebo-controlled trial, the primary end point being the spleen volume reduction by 35%, as well as the key secondary end points of total symptom score reduction and the proportion of patients who achieved a 50% reduction in their total symptom score.
0:49 | The top-line data from this study demonstrated that as compared with ruxolitinib monotherapy, there was a clear superiority of the combination therapy in terms of reducing the spleen size, which was almost a 2-fold magnitude increase in the proportion of patients whose spleen was reduced in size. I think the significance of that is that, at least historically, it has shown that there is a survival benefit that correlates with spleen volume reduction. That was not what was directly assessed with this trial, but I think that is part of what makes it important.
1:25 | With regards to symptom reduction, there was a numerical benefit in terms of the combination vs single-agent ruxolitinib, although it did not quite reach statistical significance. I think beyond those end points were some other compelling and important data, including reductions in inflammatory cytokines that we are seeing with a combination [that are] not seen quite so much with ruxolitinib alone, better hemoglobin parameters for the combination, more patients had anemia with ruxolitinib alone and better preservation with the combination therapies. [For] bone marrow fibrosis, a greater proportion of patients appeared to have an improvement in their bone marrow fibrosis with combination than what we have seen with ruxolitinib alone. I think those are kind of the key positive takeaways.
2:20 | Importantly, there were not any new adverse event signals from the combination therapy. The 1 thing that if we think about hematologic and non-hematologic toxicity, there was a little bit more thrombocytopenia seen with combination therapy, and in nonhematologic toxicities, that was observed with combination therapy than with ruxolitinib. But again, largely there [were] no new safety signals from the combination therapy over what we have seen with ruxolitinib.
Rossetti Reviews Myelofibrosis Risk Stratification and Outcome Data for Pacritinib
July 17th 2024During a Case-Based Roundtable® event, James M. Rossetti, DO, discussed the role of risk scoring and stratification tools and treatment for a patient with declining hemoglobin and platelet counts due to primary myelofibrosis.
Read More
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More
Ruxolitinib Treatment in Myelofibrosis Still Effective, Regardless of Anemia
June 21st 2024New or worsening anemia did not appear to reduce the clinical benefit of ruxolitinib in myelofibrosis patients, and the median overall survival was similar between patients with and without new or worsening anemia.
Read More
Challenging Disease Features of Myelofibrosis Lead to Use of JAK Inhibitors
June 17th 2024During a Case-Based Roundtable® event, Kristen Pettit, MD, moderated a discussion on which disease features of myelofibrosis are most challenging and when to use JAK inhibitors in the first article of a 2-part series.
Read More